Trending...
- Sycor Introduces Spring Release 2026 of Sycor.Rental with AI-Driven Innovations and Enhanced Service Processes
- Pacific Emblem Company Launches "Happy 250th Birthday America" Collection and Proud Supporter of the Gary Sinise Foundation
- Bold Beauty Project Celebrates Anniversary with Collaborative Exhibition at FIU's Miami Beach Urban Studios
WILMINGTON, N.C., May 5, 2021 /PRNewswire/ -- Isosceles Pharmaceuticals Inc. a biotechnology company dedicated to developing, commercializing, and marketing innovative non-opioid products for the treatment of mild to moderate pain and inflammatory diseases, today announced the appointment of William D. Humphries as its Chief Executive Officer. Mr. Humphries is a highly accomplished executive leader in the pharmaceutical industry with a proven track record leading several global pharmaceutical companies.
"We are excited to welcome Bill for the role of Chief Executive Officer," said Tim Wright, Chairman of Isosceles Board of Directors. "His extensive background in the pharmaceutical industry will provide invaluable leadership as Isosceles achieves its strategic growth milestones."
Most recently, Mr. Humphries served as President of Ortho Dermatologics, a subsidiary of Bausch Health Companies. He has also held global executive leadership positions at Merz North America, GlaxoSmithKline, Stiefel, and Allergan.
"I would like to thank Tim and the Isosceles team for welcoming me to company," said Mr. Humphries, Chief Executive Officer of Isosceles. "I was attracted to Isosceles by their focus on the pursuit of innovative solutions for safe, novel non-opioid pain relief and the passion the team has for delivering these important products to the market. I look forward to leveraging my experience to accelerate the company's development plans and lead Isosceles as it unlocks its full potential."
More on ncarol.com
Mr. Humphries currently serves as Chairman of the Board at Clearside Biomedical, Chairman of the North Carolina State University Global Luxury Management Board, is a member of the Board at Aclaris Therapeutics, and a member of the Board at Strata Skin Sciences. He received his MBA from Pepperdine University and completed his undergraduate studies at Bucknell University.
About Isosceles Pharmaceuticals, Inc.
Isosceles Pharmaceuticals is a preclinical stage biotechnology and medical device company focused on the delivery of drug master file backed synthetic cannabinoids for their anti-inflammatory and pain relief properties. The Company's proprietary formulations coupled with unique delivery platforms provide high bioavailability via parenteral and transdermal routes.
Investor Contact
Brett Lanier
[email protected]
SOURCE Isosceles Pharmaceuticals, Inc.
Related Links
www.isoscelespharma.com
"We are excited to welcome Bill for the role of Chief Executive Officer," said Tim Wright, Chairman of Isosceles Board of Directors. "His extensive background in the pharmaceutical industry will provide invaluable leadership as Isosceles achieves its strategic growth milestones."
Most recently, Mr. Humphries served as President of Ortho Dermatologics, a subsidiary of Bausch Health Companies. He has also held global executive leadership positions at Merz North America, GlaxoSmithKline, Stiefel, and Allergan.
"I would like to thank Tim and the Isosceles team for welcoming me to company," said Mr. Humphries, Chief Executive Officer of Isosceles. "I was attracted to Isosceles by their focus on the pursuit of innovative solutions for safe, novel non-opioid pain relief and the passion the team has for delivering these important products to the market. I look forward to leveraging my experience to accelerate the company's development plans and lead Isosceles as it unlocks its full potential."
More on ncarol.com
- AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
- BestDoc Launches AI Call Center for Healthcare
- Acuvance Appoints Sandeep Sabharwal to Board of Directors, Strengthening Leadership to Support Continued Platform Growth
- Grange Insurance Association to Rebrand as Granwest Insurance on July 1, 2026
- Dr. Rosendo Icochea, MD Recognized for Contributions to Surgical Education and Medical Research
Mr. Humphries currently serves as Chairman of the Board at Clearside Biomedical, Chairman of the North Carolina State University Global Luxury Management Board, is a member of the Board at Aclaris Therapeutics, and a member of the Board at Strata Skin Sciences. He received his MBA from Pepperdine University and completed his undergraduate studies at Bucknell University.
About Isosceles Pharmaceuticals, Inc.
Isosceles Pharmaceuticals is a preclinical stage biotechnology and medical device company focused on the delivery of drug master file backed synthetic cannabinoids for their anti-inflammatory and pain relief properties. The Company's proprietary formulations coupled with unique delivery platforms provide high bioavailability via parenteral and transdermal routes.
Investor Contact
Brett Lanier
[email protected]
SOURCE Isosceles Pharmaceuticals, Inc.
Related Links
www.isoscelespharma.com
0 Comments
Latest on ncarol.com
- $7.6 Billion US Crypto ATM Market by 2034; California and Texas Crypto ATM Deployments for Bitcoin Bancorp (Stock Symbol: BCBC); 1000 Kiosk Inventory
- MainConcept Announces Multiview Encoding for Apple Immersive Video
- CCHR Rejects Global Psychiatric Push to Electroshock Children
- iVAM2-ST2110 to Simplify IP Transitions and Reduce Monitoring Complexity
- Americans Leave Behind or Discard 42% of Their Belongings When Moving Out for the First Time, Talker Research Finds
- Central Florida Luxury Real Estate Firm DANHOLM COLLECTION Partners with Luxury Presence to Expand Global Buyer Reach
- Advantage Marketing Launches 3-Minute Assessment to Help SMBs Diagnose and Fix Marketing Gaps
- Charlotte Dad Builds AI Platform That Found $1.5M in Scholarships for His Family — Debt Free
- InterMountain Management Announces the Re-opening of Holiday Inn Express & Suites Alexandria
- New from Regal House Publishing, Gone Before You Knew Me, a biting YA about a girl who may disappear
- Nufabrx Announces Strategic Acquisition of Elos Thermal
- CB Stuffer Expands New England Footprint with Launch at Common Man Roadside in Hooksett, NH
- Contracting Resources Group Named to the 2026 Inc. Regionals: Mid-Atlantic List
- Dividend Stock Guru Unveils High Yield Dividend Stock Research Reports
- Charging Into the $30 Billion Heart Failure Market with Late-Stage Momentum, Breakthrough Data, & Strong Financial Backing: Cardiol Therapeutics $CRDL
- BumblebeeSmart Introduces Extra Large Mountain-Themed Sensory Wall Panels Set for Schools, Clinics and Family Spaces
- All American Home Renovators: Transforming Bathrooms into Masterpieces, One Home at a Time
- Bold Beauty Project Celebrates Anniversary with Collaborative Exhibition at FIU's Miami Beach Urban Studios
- Pacific Emblem Company Launches "Happy 250th Birthday America" Collection and Proud Supporter of the Gary Sinise Foundation
- Bold Beauty Project Announces Exhibition at Palazzo Mora Venice, Italy